149 COMMONWEALTH DRIVE, MENLO PARK, CA
Announces Planned Leadership Transition
Earnings Release
Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Other Events
Stockholders Approve Amendment to 2024 Incentive Award Plan
Financial Results, Reg. FD
FDA Approves Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
S-8 POS